Frequent SLIT2 promoter methylation in the serum of patients with ovarian cancer
- PMID: 22613430
- DOI: 10.1177/147323001204000231
Frequent SLIT2 promoter methylation in the serum of patients with ovarian cancer
Abstract
Objective: The slit homologue 2 (SLIT2) gene is a tumour suppressor gene. This study investigated the methylation status of the SLIT2 promoter in women with ovarian cancer in terms of identifying whether this might aid the early diagnosis of ovarian cancer.
Methods: Using methylation-specific polymerase chain reaction analysis, the methylation status of the SLIT2 promoter was measured in tumour tissue and serum samples from 36 patients with ovarian cancer and in matched serum samples from 25 controls without cancer.
Results: Aberrant methylation of the SLIT2 promoter was present in ovarian tissue from 29/36 (80.6%) ovarian cancer patients, but not in the 25 healthy controls. Among the cases with hypermethylation in their ovarian tissue, 27/29 (93.1%) of the case-matched serum DNA samples, including all four cases of early-stage ovarian cancer, showed hypermethylation of the SLIT2 promoter.
Conclusions: Hypermethylation of the SLIT2 promoter may be a relatively early event in ovarian cancer; thus, its detection may be an effective approach to improve early diagnosis.
Similar articles
-
Detection of Slit2 promoter hypermethylation in tissue and serum samples from breast cancer patients.Virchows Arch. 2011 Oct;459(4):383-90. doi: 10.1007/s00428-011-1143-5. Epub 2011 Sep 6. Virchows Arch. 2011. PMID: 21894562
-
SLIT2 is epigenetically silenced in ovarian cancers and suppresses growth when activated.Asian Pac J Cancer Prev. 2011;12(3):791-5. Asian Pac J Cancer Prev. 2011. PMID: 21627385
-
A multiplex methylation-specific PCR assay for the detection of early-stage ovarian cancer using cell-free serum DNA.Gynecol Oncol. 2013 Jul;130(1):132-9. doi: 10.1016/j.ygyno.2013.04.048. Epub 2013 Apr 25. Gynecol Oncol. 2013. PMID: 23623832
-
Promoter hypermethylation of SLIT2 is a risk factor and potential diagnostic biomarker for nasopharyngeal carcinoma.Gene. 2018 Feb 20;644:74-79. doi: 10.1016/j.gene.2017.10.059. Epub 2017 Nov 8. Gene. 2018. PMID: 29107007
-
Promoter hypermethylation of p16INK4A, p14ARF, CyclinD2 and Slit2 in serum and tumor DNA from breast cancer patients.Life Sci. 2007 Apr 24;80(20):1873-81. doi: 10.1016/j.lfs.2007.02.026. Epub 2007 Feb 27. Life Sci. 2007. PMID: 17383681
Cited by
-
Current and Emerging Strategies for Tubo-Ovarian Cancer Diagnostics.Diagnostics (Basel). 2023 Oct 28;13(21):3331. doi: 10.3390/diagnostics13213331. Diagnostics (Basel). 2023. PMID: 37958227 Free PMC article. Review.
-
High-Grade Serous Ovarian Cancer-A Risk Factor Puzzle and Screening Fugitive.Biomedicines. 2024 Jan 19;12(1):229. doi: 10.3390/biomedicines12010229. Biomedicines. 2024. PMID: 38275400 Free PMC article. Review.
-
Potential clinical utility of liquid biopsies in ovarian cancer.Mol Cancer. 2022 May 11;21(1):114. doi: 10.1186/s12943-022-01588-8. Mol Cancer. 2022. PMID: 35545786 Free PMC article. Review.
-
Methylation of cell-free circulating DNA in the diagnosis of cancer.Front Mol Biosci. 2015 Apr 22;2:13. doi: 10.3389/fmolb.2015.00013. eCollection 2015. Front Mol Biosci. 2015. PMID: 25988180 Free PMC article. Review.
-
Changes in SLIT2 expression are associated with the migration of human ovarian clear cell carcinoma cells.Oncol Lett. 2021 Jul;22(1):551. doi: 10.3892/ol.2021.12812. Epub 2021 May 24. Oncol Lett. 2021. PMID: 34093772 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical